Glucagon-like peptide-1 (GLP-1) receptor agonists are a class of medications originally developed for managing type 2 diabetes mellitus and, more recently, some have been approved for weight management
Research Insights Superior Weight Loss Outcomes In a 48-week phase 2 study, adults with obesity treated with retatrutide experienced mean weight reductions of 22.8% (8 mg dose) and 24.2% (12 mg dose), outperforming other weight loss medications
However, DSS never began covering these drugs for weight loss
Number 1 Peptide mass (mg) This is the amount of peptide in the vial, printed on the label: 5 mg, 10 mg, 15 mg, and so on
Its anticipated that Retatrutide UK pricing will follow a similar tiered structure based on the required dosage once it enters the market